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Abstract
Patients with poor risk acute myeloid leukemia (AML) have a dismal outcome. We hypothesized that combining decitabine with
a standard non-myeloablative (NMA) conditioning regimen prior to allogeneic hematopoietic cell transplantation (allo HCT),
might decrease the relapse incidence. We conducted a multicenter prospective phase II study (NCT02252107) with 10-day
decitabine (20mg/m2/day) integrated in a standard non-myeloablative conditioning regimen (3 days fludarabine 30mg/m2 with 2
Gray total body irradiation (TBI)). Patients with AML ≥ 18 years in 1st (in)complete remission (CR/CRi) with a poor or very
poor risk profile, as defined by the HOVON-132 protocol, were eligible. Results: Forty-six patients (median age 60; range
23–74) were included. Median follow up time was 44 months (range 31–65 months). The cumulative 1-year incidence of relapse
and NRM were respectively 23% and 11%. Incidence of grade III-IV acute graft-vs-host-disease (GVHD) and severe chronic
GVHD were 13% and 20%, respectively. One-year OS was 70%. Application of ELN 2017 risk classification to the study cohort
revealed a cumulative one-year relapse rate of respectively 31% and 13% for the adverse and intermediate risk patients. To
conclude, the 10-day DEC/FLU/TBI conditioning regimen prior to allo HCT in poor risk AML patients is effective and feasible.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease
with different molecular and genetic abnormalities, that define
the various disease risk groups. Patients that pertain to an
adverse or poor risk group have a dismal outcome, despite
allogeneic hematopoietic cell transplantation (allo HCT), with
a 5-year overall survival (OS) of 19–46% [1, 2]. This dismal
outcome is mainly due to the high relapse rate (40–68%) in
these patients. Choosing the optimal conditioning regimen
prior to allo HCT is challenging and its choice is influenced
by various factors, such as, age of the patient, performance
status and comorbidities, disease risk, remission status at the
time of transplantation, and donor type [3].
Over the past decade, many studies have been carried out
on different conditioning approaches focused on reducing
the relapse rate in conjunction with a low non-relapse
mortality (NRM) rate. The Seattle team has introduced total
body irradiation (TBI) (2 Gy) in combination with fludar-
abine (FLU) as a non-myeloablative (NMA) conditioning
prior to allo HCT in older patients. A report on 274 AML
patients conditioned with FLU-TBI 2 Gy has shown 26%
NRM, 42% relapse and 37% survival [4]. Although this
conditioning regimen is considered well suited for older
patients with AML and comorbidities, it is currently con-
sidered a suboptimal regimen for many patients, because of
the high risk of relapse.
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Comparison of myeloablative conditioning (MAC) with
reduced intensity conditioning (RIC) regimens in patients
with (poor risk) AML has yielded contradictory results
[2, 5–11]. Some of these studies showed that higher relapse
risk with RIC allo HCT was counterbalanced by higher
NRM in MAC allo HCT, resulting in comparable OS.
Although two recent studies showed superiority of the
MAC conditioning regimen compared to the RIC con-
ditioning regimen, this superiority was not apparent in
patients with high risk disease and not in patients older than
60 years [7, 8]. Furthermore, measurable residual disease
(MRD) at start of conditioning prior to allo HCT, has shown
to be an important factor predicting relapse risk [6, 9–11],
although not all of the studies pointed in the same direction
regarding the question if MAC SCT would result in better
outcome. So, AML patients with high risk disease and with
MRD prior to start conditioning regimen currently have a
high relapse rate, which is not overcome by MAC.
Apparently, novel treatment concepts are needed, espe-
cially for (unfit and/or MRD positive) AML patients with
poor risk disease. We previously hypothesized that combining
a NMA conditioning regimen with the hypomethylating agent
(HMA) 5-aza-2′-deoxycitidine (decitabine) could be promis-
ing, especially since decitabine treatment had little extra-
medullary toxicity, has immune modulating properties and
good efficacy against (high risk) AML [12]. In our pilot study
with 10-day decitabine added to the NMA FLU/TBI regimen
(DEC/FLU/TBI), we demonstrated that this conditioning
regimen was feasible and effective [13]. One of the immune
modulating actions of HMA is the upregulated expression of
epigenetically silenced tumor-associated antigens (TAA) [14],
which is interesting because these TAA are tumor-restricted
and may have an immunogenic potential, that is important for
the graft-vs-leukemia (GVL) effect. In our DEC/FLU/TBI
pilot study several TAA- specific CD8(+) T cells were
observed after allo HCT. We think this immunologic effect of
decitabine making silenced TAA visible for the donor
immune system, contributes to disease control post trans-
plantation. Stimulated by our preliminary data with the DEC/
FLU/TBI conditioning regimen we initiated this phase II
study (NCT02252107). In this study we added 10 days of
decitabine to the standard NMA conditioning with fludar-
abine/ 2 Gy TBI in patients with poor or very poor risk AML
to reduce 1-year relapse rate.
Methods
Study design and patient selection
This prospective phase II, multicenter, single arm, interven-
tion study was performed from October 2014 until October
2020 at the departments of Hematology of the Radboud
University Medical Center Nijmegen (The Netherlands), the
University Medical Center Groningen (The Netherlands) and
the University of Liège (Belgium). Adult patients with poor
or very poor risk AML were included if they were in first (in)
complete remission at study entry (CR/CRi), and if eligible to
receive an allo HCT. Poor risk AML was defined according
to the HOVON-132 protocol (www.hovon.nl); i.e., abnormal
karyotype (non core-binding factors) or white blood cell
count (WBC) > 100 × 109/L or no early remission (i.e., CR
after 1st cycle of intensive chemotherapy). Very poor risk
AML was defined as AML with one or more of the following
characteristics: monosomal karyotype, abnormal 3q26, EVI1
overexpression, TP53 mutation, RUNX1 mutation, ASXL1
mutation or FLT3-ITD with a FLT3-ITD/FLT3wt ratio > 0.6.
Patients with active and uncontrolled infections or infections
with HIV, HBV, HCV were excluded. Patients were not
eligible if they had received an hypomethylating agent before
start of the study protocol, only “3+ 7” based remission
induction schedules were allowed.
Study protocol
Patients received 10-day decitabine (20 mg/m2/day) in
addition to the NMA conditioning regimen, developed by
the Fred Hutchinson Cancer Research Center (Seattle),
consisting of 3 days fludarabine 30 mg/m2 and 2 Gray TBI
(Fig. 1). All donors were 9/10 or 10/10 HLA matched sib-
ling or unrelated donors. Anti-thymocyte globulin (ATG) (2
mg/kg, during 4 consecutive days) was added when the
donor was a (9/10) mismatched unrelated donor. Post
grafting immunosuppression consisted of mycophenolate
mofetil and cyclosporine. If patients had measurable residual
disease (MRD) at start of the conditioning regimen, a bone
marrow examination was repeated at day -1 or day 0 (= day
of transplant) to define the MRD status directly after the
decitabine treatment, before allografting. MRD was assessed
with flow cytometry and was defined positive if the leuke-
mia associated phenotype was >0.1%, as defined by the
ELN MRD working party [15]. At day +21, +40, + 180,
+365 after allo HCT and at relapse the following data were
collected: bone marrow evaluation, donor T cell chimerism
(assessed on whole peripheral blood using real time PCR
with allele-specific primers for DNA-sequences containing
single nucleotide polymorphisms (SNPs)), laboratory
results, adverse events, survival status, and the occurrence of
graft-versus-host disease (GVHD). Successful engraftment
was defined according to European Bone Marrow Trans-
plant (EBMT) criteria of hematopoietic repopulation [16].
Acute GVHD (aGVHD) was graded according to the criteria
of Harris et al. [17] and chronic GVHD (cGVHD) was
classified according to the NIH scoring system [18]. Safety
endpoints were scored according to CTCAE 4.0. In case
patients had a transplant rejection they went off-study.
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Endpoints
Primary study endpoint was cumulative 1-year relapse
incidence. Relapse following CR is defined as reappearance
of blasts in the blood or the finding of more than 5% blasts
in the bone marrow (BM), not attributable to another cause.
Secondary endpoints were NRM, OS and relapse-free
and GVHD-free survival (GRFS). NRM, relapse-free sur-
vival (RFS), and OS were defined according to ELN criteria
[19]. GRFS was defined as surviving the first 12 months
after allo HCT without relapse and without grade III-IV
aGVHD and/or severe cGVHD [20].
Statistics
Historically relapse rate is about 55% in poor and very poor
risk subgroups after allo HCT. Among others Cornelissen
et al. report 43% relapse at 5 year in unfavorable karyotype
patients and 68% in monosomal karyotype patients [1]. We
hypothesized that the relapse rate would decrease from
about 55% to 27% (Hazard ratio (HR) 0.5) by adding
decitabine to the standard Flu/TBI schedule. Based on our
preliminary data we found it justified to aim for a 1-sided
alfa of 5% and we assumed a NRM of 15%. In the per-
spective of these assumptions we calculated, using a’Hern’s
Single Stage Phase II design, that 45 patients need to be
included to demonstrate a decrease in relapse (at 1 year) of
55% to 33% (HR 0.6).
Descriptive statistics were used to characterize the
cohort. A competing risk analysis was performed to obtain
relapse incidence estimates with death and rejection as a
competing risk. The Kaplan-Meier statistics was used to
obtain estimates for OS, RFS, and GRFS. A p value smaller
than 0.05 was considered statistically significant. Analyses
were done with SAS ® 9.4 and IBM SPSS Statistics 25.
This study was carried out in The Netherlands and
Belgium in accordance with the applicable rules concerning
the review of research ethics committees and informed
consent. The trial was registered at www.clinicaltrials.gov
(NCT02252107).
Results
Patient and disease characteristics
Forty-six patients with a median age of 60 years (range
23–74) were included between 2014 and 2018. A summary
of the patient and disease characteristics is shown in
Table 1. Three patients received a mismatched allograft and
therefore received ATG (8 mg/kg) in their conditioning, all
other patients received DEC/Flu/TBI without ATG.
Seventeen AML patients (37%) were classified as poor and
29 patients (63%) as very poor risk AML according to the
HOVON-132 risk classification. Of all patients, 29 patients
(63%) did not have a CR after 1 cycle of intensive induction
chemotherapy, 7 patients (15%) had a WBC > 100 × 109/L
at diagnosis, and 31 patients (67%) had an abnormal kar-
yotype or molecular mutations, of whom 6 patients (13%) a
monosomal karyotype and 9 patients (20%) a complex
abnormal karyotype. Twenty-nine patients (63%) had 2 or
more of these high risk features. According to the later
defined European LeukemiaNET (ELN) 2017 criteria for
defining the cytogenetic/molecular risk in AML [19], we re-
classified patients according to the ELN2017 criteria.
Twenty-nine patients (63%) were classified as adverse risk,
14 patients (30%) as intermediate, and 3 patients (7%) as
favorable risk. All 3 ELN favorable patients that were
included in this protocol as ‘poor risk’ patients had a NPM1
mutation with/or without a (low allelic burden, ratio < 0.5)
FLT-3 ITD mutation. They were eligible because they were
> 60 years of age (n= 2), had not achieved an early CR
(n= 2) and presented with hyperleukocytosis (n= 2).
Outcome
Median follow up was 44 months (range 31–65 months).
Eleven patients (23%) had a relapse within the first year
after allo HCT (see Fig. 2a–c). In total, 13 patients relapsed.
Median time until relapse was 130 days (range 3–592).
Eight out of these 13 patients (62%) had very poor risk
disease. One of the relapsed patients received ATG pre
Day -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0
Decitabine
20mg/m2 1 2 3 4 5 6 7 8 9 10
Fludarabine
30mg/m2 1 2 3
TBI1 2 gray x
Stem cell infusion x
Fig. 1 The DEC/FLU/TBI regimen. At day -11, decitabine (DEC)
was started for 10 days, followed by fludarabine (FLU) at day -4 for 3
days and total body irradiation (TBI) 2 gray at day -1. At day 0, the
stem cells were infused. In case a mismatched unrelated donor was
used, also anti-thymocyte globulin (ATG) 2 mg/kg was added at day
-8 for 4 consecutive days.
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allografting. Of the 29 patients with adverse risk according
to ELN 2017 criteria, 9 patients (31%) developed a relapse.
Seventeen patients were in CRi at start of conditioning, and
6 (35%) of these patients had a relapse, versus 6 (21%) of
the 29 patients that were in CR. NRM was 5% within the
first 100 days post HCT, and 11% within the first year post
allo HCT. One-year OS, RFS, and GRFS were 70%, 66%,
and 45% respectively (see Fig. 3a). After 4 year this was
56%, 52% and 26% respectively. One-year OS in poor and
very poor risk patients according to HOVON-132 criteria
was 88% and 59% respectively. When the ELN-2017 cri-
teria were applied on this cohort, the one-year OS for the
adverse risk was 55% and the one-year OS for the non-
adverse group was 94%. (see Fig. 3b, c). During the follow-
up, 18 patients died, 11 due to relapse, 3 due to GVHD, 2
due to infection, 1 due to heart failure and 1 due to suicide.
MRD conversion
Fourteen patients (30%) were MRD positive at the start of
conditioning, and in 10 of these patients the MRD status
was repeated at day -1/day 0. Seven of them became MRD
negative. None of these 7 patients, who became MRD-,
developed a relapse during the follow up of the study. The 1
year OS for MRD+ and MRD- patients (as measured at t=
0, allo HCT) was respectively 50% and 74%.
Transplant related complications and adverse events
The in-hospital stay during conditioning/allografting had a
median duration of 19 days (range 1–72). Twenty-four
(52%) and 37 (80%) patients had full engraftment before
day 21 and day 40 respectively. Rejection was seen in 3
patients (7%) at day 40, day 52 and day 117, respectively.
Table 1 Patient characteristics.







Median (range) 60 (23–74) 60 (23–74) 62 (29–71)
≥60 years 24 (52) 15 (52) 9 (53)
Male 24 (52) 16 (55) 8 (47)
Type of disease
De novo AML 41 (89) 27 (93) 14 (82)




4 (9) 4 (14) 0 (0)
AML with myelodysplasia
related changes
15 (32) 10 (35) 5 (29)
Therapy-related myeloid
neoplasms
4 (9) 3 (10) 1 (6)
AML, not otherwise
specified
22 (48) 12 (41) 10 (59)
Myeloid sarcoma 1 (2) 0 (0) 1 (6)
Disease status at start of
conditioning
Complete remission (CR) 29 (63) 20 (69) 9 (53)
Incomplete remission
(CRi)








116 (54–190) 115 (54–190) 121 (90–163)
MRDa status pre decitabine
Negative 30 (65) 17 (59) 13 (77)
Positive 14 (31) 10 (34) 4 (23)
Missing 2(4) 2 (7) 0 (0)
MRDa after 10 days of
decitabine at t= 0
Negative 37 (81) 20 (69) 17 (100)
Positive 2 (4) 2 (7) 0 (0)
Unknown 7 (15) 7 (24) 0 (0)
Extra medullar disease
Yes 2 (4) 0 (0) 2 (12)
Sorror co-morbidity index
(HCT-CI)
Median (range) 2 (0–8) 2 (0–8) 1 (0–6)
≤2 29 (63) 19 (66) 10 (59)
≥3 17 (37) 10 (34) 7 (41)
EBMT risk score
(Grathwohl score)
Median (range) 2 (0–4) 2 (0–4) 2 (1–4)
≤2 31 (67) 18 (62) 13 (77)
≥3 15 (33) 11 (38) 4 (23)
Donor type
Matched 10/10
SIBb 16 (35) 12 (41) 4 (24)
MUDc 27 (59) 17 (59) 10 (59)
Mismatched 9/10
MMUDd 3 (6) 0 (0) 3 (17)
Median donor age (range) 32 (19–66) 32 (21–66) 32 (19–63)
Donor sex
male 25 (54) 15 (52) 10 (59)
CMV positive donor
CMV neg patient 8 (18) 5 (17) 3 (18)
CMV pos patient 14 (30) 9 (31) 5 (29)
Table 1 (continued)







CMV neg patient 14 (30) 6 (21) 8 (47)
CMV pos patient 10 (22) 9 (31) 1 (6)
EBV positive donor
EBV neg patient 5 (11) 2 (7) 3 (18)
EBV pos patient 38 (83) 25 (86) 13 (76)
EBV negative donor
EBV neg patient 0 (0) 0 (0) 0 (0)
EBV pos patient 3 (6) 2 (7) 1 (6)
Stem cell source (%)
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Of these 3 patients 2 had received bone marrow stem cells
from a matched donor and 1 patient had received peripheral
blood stem cells from a matched donor. Twenty patients
(44%) developed aGVHD gr I-IV after a median of 53 days
(range 12–350). Grade III-IV aGVHD was seen in 6
patients (13%), and 2 of them eventually died due to
aGVHD. Twenty-three (50%) patients developed any grade
of cGVHD, and this was graded as severe in 9 (20%) of
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Fig. 2 Incidence of AML relapse during follow up. a Relapse incidence
for all patients, n= 46. b Relapse incidence in patients with poor (solid
line) and very poor (dashed line) risk disease, as defined in the method
section. c Relapse incidence in patients with adverse (solid line) and
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Fig. 3 Overall survival (OS), relapse-free survival (RFS), and
graft-vs-host-free and relapse-free survival (GRFS). a OS, RFS,
and GRFS for all patients. b OS for patients with poor (solid line) and
very poor (dashed line) risk AML. c OS for patients with adverse risk
(dashed line) and no-adverse (solid line) risk AML according to the
ELN 2017 criteria.
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events that were seen in >5% of patients were febrile neu-
tropenia (9%) and other infections (9%).
Discussion
In this phase II intervention study a 10-day decitabine
regimen was added to the standard NMA conditioning
(DEC/FLU/TBI) before allografting in poor risk AML
patients already in CR/CRi, with the hypothesis that dee-
pening of remission before allografting and immune mod-
ulation of remaining disease would reduce relapse rate. We
observed an AML relapse rate of 23% and a NRM of 11%
in the first year after allo HCT. The 1-year OS, RFS, and
GRFS were 70%, 66% and 45% respectively.
Former studies reported relapse rates of 40–68% in poor
risk AML patients and OS of 29–54% and 22–40% after
MAC and NMA allo HCT respectively [1, 2, 5, 6]. In our
study population with a mature median follow up of
44 months, the 4-year OS was 56% after NMA condition-
ing. The comparison with other studies on poor risk AML is
not straightforward, due to the use of different risk criteria.
In addition, NMA and MAC regimens are often compared
in a retrospective manner. This could lead to selection bias,
since older AML patients more often undergo NMA allo
HCT compared to younger patients [5, 7]. After the intro-
duction of the new ELN 2017 risk classification criteria we
redefined our patients according to ELN risk, and found that
the poor and very poor risk groups corresponded well with
the ELN intermediate and adverse risk group respectively,
overlapping in 83% of cases. Applying the ELN risk criteria
on our study cohort, 1-year relapse rate was still low in the
adverse risk group (31%), with a 1-year OS of 56% and a 4-
year OS of 45%. To compare, a retrospective study of
Yanada et al. found a 1-year relapse rate of >40% in poor
risk patients, and a 1-year OS of nearly 50% with MAC and
30% with NMA conditioning [2]. In this light our results
seem encouraging as an alternative approach. Also in
younger patients with poor risk disease, it could be argued
whether our new regimen would be preferable. A study by
Konuma et al. with patients with high risk disease found a
better OS after MAC conditioning compared to NMA
conditioning (3-year OS MAC 54%/RIC 40%), although
this effect was only seen in patients younger than 60 years
of age and in cytogenetic negative CR [6]. Gilleece et al.,
concluded as well that NMA HCT was inferior to MAC,
although only in the MRD positive patients under the age of
50 [9]. So, the impact of MRD is evident, although the
impact of MAC to improve outcome in these patients seems
unclear.
In our cohort, when comparing MRD status pre- and post
decitabine conditioning, we found that 7 of 10 MRD
positive patients became MRD negative directly after
10 days of decitabine. It would be interesting to investigate
in a larger cohort if the addition of decitabine can indeed
increase the number of patients that become MRD negative
prior to allografting and if this could explain our lower rate
of relapses and improved survival. In a previously study, we
showed that the use of decitabine with NMA conditioning
improves the amount of CD8 positive T cells against TAAs
[13], which is an interesting example of one of the immu-
nologic actions of HMA. In the past it had been shown that
HMAs can increase the expression of these epigenetically
silenced TAA on tumor cells and also of minor histo-
compatibility antigens (MiHAs) [14, 21]. We think that the
residual tumor cells after decitabine treatment, with
increased TAA and MiHA expression, can eventually lead
to presentation of these peptides by antigen-presenting cells,
and evoke an donor-derived T cell response against these
antigens. This might lead to increased immune clearance of
leukemic blasts and could provide an explanation for the
lower relapse rates observed.
Furthermore, we showed that the addition of decitabine
did not increase NRM (1-year NRM 11%), compared to
standard NMA conditionings [3, 4]. This is also an
important finding, since many of our patients cannot tolerate
a more toxic regimen, especially in older patients or patients
with comorbidities. Recently D’angelo et al. [22] concluded
that they found a high risk of infection (55% grade 3–4
infections) and mortality (25% survival after a median fol-
low up of 3.6 years) after decitabine induction, however, in
their protocol patients received decitabine 17–24 days
before start MAC conditioning, with all patients becoming
neutropenic after decitabine. We started the conditioning
with 10 days of decitabine and directly continued with a
NMA regimen. So, the duration of neutropenia was shorter
in our patients, and also antibiotic prophylaxis was given
during this period. This might explain the low NRM in our
cohort as well as the lower amount of severe infections (9%
grade 3–4 infections and 9% febrile neutropenia).
A limitation of our study is the relatively low number of
patients we included, although this was based on a power
calculation to demonstrate a relapse reduction (of 55% to
33%; HR 0.6) after 1 year compared to historical results.
Unfortunately we cannot extract patients of 60 years or
older for a meaningful sub-analysis and compare this sub-
group with former research on poor risk disease in older
patients that received NMA HCT.
In summary, in this prospective phase 2 study we found
that addition of 10-day decitabine to NMA conditioning
seems to be a safe strategy that might add to lower relapse
rates in patients with poor or very poor risk AML who
receive an allo HCT. Future research is necessary to confirm
if this schedule indeed can decrease relapse, especially in
elderly poor risk AML patients, and in those with MRD
positive disease prior to conditioning.
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